We should take a guarded approach in investing. We are talking about a company with almost no success bringing products to market. OTOH, between Oral-lyn and the various vaccine research past, present and pending, there is a ton of potential. A Covid vaccine trial could certainly light the fuse. I think it will be intriguing to see the market reaction with trial news. Will it be muted as per we have grown accustomed to or will the potential safety and efficacy stand out vs PFE, AZ, Moderna and the rest?
I am undecided about the bonus. I do believe the timing is interesting given the PPS downward trajectory at the time the shares were "awarded", and the January 31 date as well given the CC date of 2/5. Is it a coincidence? Granted we do not know the terms associated with the shares. I want to believe the award was provided because they knew the work that was done throughout 2020 was going to create significant shareholder value in early 2021.
(5)
(0)
Generex Biotechnology Corp. (GNBTQ) Stock Research Links